Northern Ireland's Health & Life Sciences sector: From innovation to scale

Northern Ireland's Health and Life Sciences sector has attracted considerable attention in recent years, and with good reason. We have a number of internationally recognised success stories across pharmaceuticals, diagnostics, medtech and digital health, alongside a strong research base and an increasingly sophisticated ecosystem supporting innovation.

It would be easy to focus solely on individual company success stories, but that risks overlooking what is really driving growth in the sector. In our view, the real opportunity lies in the strength of the ecosystem as a whole and the way in which academia, healthcare, industry, regulators and investors increasingly work together to drive growth.

One of NI’s strengths is that it is large enough to support innovation, but still small enough for the key players across academia, healthcare and industry to work closely together. Our universities produce world-class research, our healthcare system provides valuable opportunities for clinical engagement and innovation, and the sector benefits from both indigenous companies with global reach and international businesses that have chosen to invest here. When these elements work together effectively, they create an environment capable of taking an idea from research through to commercialisation. Ultimately, that is what will determine the long-term success of the sector. Generating innovation is important, but creating successful businesses from that innovation is what drives sustainable economic growth.

The challenge, as is often the case in NI , is not innovation. It is scaling. We have no shortage of talented researchers, entrepreneurs and innovative businesses. The question is how we create conditions that allow more of them to grow and succeed. For many founders and management teams, the difficult part comes after the innovation itself: securing growth capital, protecting intellectual property, navigating regulatory requirements and finding the right route to market.

Against that backdrop, a particularly positive development for the sector has been the establishment of a Medicines and Healthcare Products Regulatory Agency (MHRA) presence in Belfast. While perhaps not attracting the same headlines as a major funding announcement or inward investment project, it is a development that should not be underestimated.

The decision to establish a base in NI is a welcome recognition of the growing importance of the region within the wider UK life sciences landscape. It also demonstrates confidence in the strength of the life sciences community and highlights the role NI can play in supporting innovation in areas such as clinical trials, medical devices, diagnostics and advanced therapies.

For businesses developing new products and technologies, having greater access to regulatory expertise is undoubtedly a positive development. Increasingly, regulatory strategy is not simply a compliance issue to be addressed towards the end of a product's development journey. It is a critical commercial consideration that can influence investment decisions, market access opportunities and ultimately the value of a business. The presence of the MHRA in Belfast reinforces the message that NI is a serious location for life sciences innovation and growth.

Northern Ireland's unique position in the post-Brexit landscape also continues to create opportunities. While navigating regulatory requirements across different jurisdictions can undoubtedly introduce complexity, the ability to engage with both UK and EU markets remains a significant attraction for many businesses. This is particularly relevant in areas such as clinical research, manufacturing and supply chain management, where cross-border activity is often an essential part of the business model.

If there is one consistent feature across the sector, it is the importance of collaboration. No single organisation can build a thriving life sciences sector on its own. Progress depends on strong connections between research institutions, start-ups, established businesses, clinicians, investors and regulators. From a legal and commercial perspective, the way these relationships are structured - whether through licensing, joint ventures or strategic partnerships - can be critical to long-term success.

Looking ahead, NI has much of what a successful Health & Life Sciences sector requires: a strong research base, innovative businesses, increasing investor interest and growing regulatory engagement.

The challenge is ensuring that more of those businesses can scale successfully. In practical terms, that means continuing to improve access to capital, attracting experienced leadership, strengthening international connections and supporting businesses through the difficult transition from innovation to commercial success.

If there is one lesson from the sector's progress to date, it is that success depends on collaboration. The stronger the connections between research, regulation, investment and industry, the greater the opportunity for Northern Ireland to establish itself as one of the most dynamic Health & Life Sciences locations across these islands.

For businesses, investors and innovators alike, that is an opportunity worth paying attention to.

For further information in relation to this topic, please contact Catherine Irvine, Partner, Micaela Diver, Partner or Hannah McDaid, Senior Associate.

Date published: 6 October 2026